760 related articles for article (PubMed ID: 10374221)
1. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses.
Sarrel P; Dobay B; Wiita B
J Reprod Med; 1998 Oct; 43(10):847-56. PubMed ID: 9800666
[TBL] [Abstract][Full Text] [Related]
3. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.
Liu J; Allgood A; Derogatis LR; Swanson S; O'Mahony M; Nedoss B; Soper H; Zbella E; Prokofieva SV; Zipfel L; Guo CY
Fertil Steril; 2011 Jan; 95(1):366-8. PubMed ID: 20850731
[TBL] [Abstract][Full Text] [Related]
5. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.
Barrett-Connor E; Young R; Notelovitz M; Sullivan J; Wiita B; Yang HM; Nolan J
J Reprod Med; 1999 Dec; 44(12):1012-20. PubMed ID: 10649811
[TBL] [Abstract][Full Text] [Related]
6. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
7. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
8. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms.
de Paula FJ; Soares JM; Haidar MA; de Lima GR; Baracat EC
Maturitas; 2007 Jan; 56(1):69-77. PubMed ID: 16822626
[TBL] [Abstract][Full Text] [Related]
9. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being.
Flöter A; Nathorst-Böös J; Carlström K; von Schoultz B
Climacteric; 2002 Dec; 5(4):357-65. PubMed ID: 12626215
[TBL] [Abstract][Full Text] [Related]
10. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
Simon JA; Stevens RE; Ayres SA; Phelps KV
Climacteric; 2001 Mar; 4(1):19-27. PubMed ID: 11379374
[TBL] [Abstract][Full Text] [Related]
11. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
12. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
Stevenson JC; Durand G; Kahler E; Pertyński T
Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
[TBL] [Abstract][Full Text] [Related]
13. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women.
Warnock JK; Swanson SG; Borel RW; Zipfel LM; Brennan JJ;
Menopause; 2005; 12(4):374-84. PubMed ID: 16037752
[TBL] [Abstract][Full Text] [Related]
14. Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report.
Carranza-Lira S; Gooch AL; Velasco-Díaz G; Solano J; Arzola-Paniagua A
Int J Fertil Womens Med; 2006; 51(4):171-5. PubMed ID: 17184102
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women.
Dobs AS; Nguyen T; Pace C; Roberts CP
J Clin Endocrinol Metab; 2002 Apr; 87(4):1509-16. PubMed ID: 11932273
[TBL] [Abstract][Full Text] [Related]
17. Sex hormones in postmenopausal women receiving low-dose hormone therapy: the effect of BMI.
Lambrinoudaki I; Armeni E; Rizos D; Deligeoroglou E; Kofinakos P; Kaparos G; Alexandrou A; Creatsa M; Logothetis E; Kouskouni E
Obesity (Silver Spring); 2011 May; 19(5):988-93. PubMed ID: 20948523
[TBL] [Abstract][Full Text] [Related]
18. Safety of estrogen/androgen regimens.
Simon JA
J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876
[TBL] [Abstract][Full Text] [Related]
19. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
Helgason S
Acta Obstet Gynecol Scand Suppl; 1982; 107():1-29. PubMed ID: 6282033
[TBL] [Abstract][Full Text] [Related]
20. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
